A case of cutaneous plasmacytoma treated with thalidomide

Eul Sang Hwang, Sang Wook Son, Il-Hwan Kim

Research output: Contribution to journalArticle

Abstract

Cutaneous involvement has been reported in all types of malignant plasma cell disorders including multiple myeloma, solitary myeloma of bone, plasma cell leukemia, and extramedullary plasmacytoma. But metastatic plasmacytomas in the skin are rare in multiple myeloma and extramedullary plasmacytoma. If skin tumors appear during the course of multiple myeloma, these should be interpreted as a sign of poor prognosis. Treatment of patients with resistant multiple myeloma is challenging. Thalidomide has recently shown antitumor activity in patients with refractory myeloma. Until the introduction of thalidomide, no drugs other than cytotoxic agents and glucocorticoids had shown antitumor activity to cutaneous plasmacytoma. We recently performed a clinicopathologic study of a patient with cutaneous involvement of multiple myeloma and reported our result with thalidomide therapy in this patient.

Original languageEnglish
Pages (from-to)1325-1328
Number of pages4
JournalKorean Journal of Dermatology
Volume42
Issue number10
Publication statusPublished - 2004 Oct 1

Fingerprint

Thalidomide
Plasmacytoma
Multiple Myeloma
Skin
Plasma Cell Leukemia
Cytotoxins
Plasma Cells
Glucocorticoids
Bone and Bones
Therapeutics
Pharmaceutical Preparations
Neoplasms

Keywords

  • Cutaneous plasmacytoma
  • Thalidomide

ASJC Scopus subject areas

  • Dermatology

Cite this

A case of cutaneous plasmacytoma treated with thalidomide. / Hwang, Eul Sang; Son, Sang Wook; Kim, Il-Hwan.

In: Korean Journal of Dermatology, Vol. 42, No. 10, 01.10.2004, p. 1325-1328.

Research output: Contribution to journalArticle

@article{016bbda9da324af9ae4dfed97670dbed,
title = "A case of cutaneous plasmacytoma treated with thalidomide",
abstract = "Cutaneous involvement has been reported in all types of malignant plasma cell disorders including multiple myeloma, solitary myeloma of bone, plasma cell leukemia, and extramedullary plasmacytoma. But metastatic plasmacytomas in the skin are rare in multiple myeloma and extramedullary plasmacytoma. If skin tumors appear during the course of multiple myeloma, these should be interpreted as a sign of poor prognosis. Treatment of patients with resistant multiple myeloma is challenging. Thalidomide has recently shown antitumor activity in patients with refractory myeloma. Until the introduction of thalidomide, no drugs other than cytotoxic agents and glucocorticoids had shown antitumor activity to cutaneous plasmacytoma. We recently performed a clinicopathologic study of a patient with cutaneous involvement of multiple myeloma and reported our result with thalidomide therapy in this patient.",
keywords = "Cutaneous plasmacytoma, Thalidomide",
author = "Hwang, {Eul Sang} and Son, {Sang Wook} and Il-Hwan Kim",
year = "2004",
month = "10",
day = "1",
language = "English",
volume = "42",
pages = "1325--1328",
journal = "Korean Journal of Dermatology",
issn = "0494-4739",
publisher = "Korean Dermatological Association",
number = "10",

}

TY - JOUR

T1 - A case of cutaneous plasmacytoma treated with thalidomide

AU - Hwang, Eul Sang

AU - Son, Sang Wook

AU - Kim, Il-Hwan

PY - 2004/10/1

Y1 - 2004/10/1

N2 - Cutaneous involvement has been reported in all types of malignant plasma cell disorders including multiple myeloma, solitary myeloma of bone, plasma cell leukemia, and extramedullary plasmacytoma. But metastatic plasmacytomas in the skin are rare in multiple myeloma and extramedullary plasmacytoma. If skin tumors appear during the course of multiple myeloma, these should be interpreted as a sign of poor prognosis. Treatment of patients with resistant multiple myeloma is challenging. Thalidomide has recently shown antitumor activity in patients with refractory myeloma. Until the introduction of thalidomide, no drugs other than cytotoxic agents and glucocorticoids had shown antitumor activity to cutaneous plasmacytoma. We recently performed a clinicopathologic study of a patient with cutaneous involvement of multiple myeloma and reported our result with thalidomide therapy in this patient.

AB - Cutaneous involvement has been reported in all types of malignant plasma cell disorders including multiple myeloma, solitary myeloma of bone, plasma cell leukemia, and extramedullary plasmacytoma. But metastatic plasmacytomas in the skin are rare in multiple myeloma and extramedullary plasmacytoma. If skin tumors appear during the course of multiple myeloma, these should be interpreted as a sign of poor prognosis. Treatment of patients with resistant multiple myeloma is challenging. Thalidomide has recently shown antitumor activity in patients with refractory myeloma. Until the introduction of thalidomide, no drugs other than cytotoxic agents and glucocorticoids had shown antitumor activity to cutaneous plasmacytoma. We recently performed a clinicopathologic study of a patient with cutaneous involvement of multiple myeloma and reported our result with thalidomide therapy in this patient.

KW - Cutaneous plasmacytoma

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=10644245142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10644245142&partnerID=8YFLogxK

M3 - Article

VL - 42

SP - 1325

EP - 1328

JO - Korean Journal of Dermatology

JF - Korean Journal of Dermatology

SN - 0494-4739

IS - 10

ER -